Abstract 572P
Background
Colorectal cancer (CRC) is a heterogeneous disease with multiple subtypes that differ in their clinical and molecular features. The presence of neoantigens derived from somatic mutations is a promising avenue for immunotherapy in CRC. However, the heterogeneity of the neoantigen landscape among CRC subtypes remains unclear.
Methods
We analyzed the whole-genomes and transcriptomes of 1063 CRC patients from a Swedish large cohort. HLA alleles were called by at least two HLA callers including HLA-HD, HLA-LA, Kourami, OptiType, PHLAT, Polysolver, xHLA for each patient. Neoantigens were predicted by pVACseq pipeline using the default settings.
Results
In total, 83,630 MHC class I neoantigens derived from 29,106 mutations (511,159 mutations were inputted) were predicted in 979 patients. Average 6.1 neoantigens were from 4,480 frameshift INDELs while only average 2.3 neoantigens were from 24,276 SNVs. Patients older than 80 years carried more neoantigens than those under 65 years, and women tended to have more neoantigens than men (Wilcoxon test, P<0.01). Tumor neoantigen burden was significantly higher in right-colon, stage II, and hypermutated (HM) tumors (P<0.0001). In total, 850 mutations were predicted to generate neoantigens in at least two patients, including KRAS G12D (6.3%), RNF43 G659X (6.1%), KRAS G12V (5.2%), TBC1D23 K647X (2.9%), and MSH3 K381X (2.8%). Neoantigen numbers from PODXL2 and CRAT mutations were significantly higher in consensus molecular subtype (CMS) 3 tumors, whereas neoantigens from JAG2 mutations were more common in CMS2 (chi-square test, P <0.05). Neoantigens derived from DNAH3, KRAS and ERBB2 mutations (37%, 47% and 52% respectively) in non-HM patients were significantly more than those (5%, 14% and 13% respectively) in HM patients. Furthermore, in stage I-III, nHM patients (n=11) with DNAH3 neoantigens have significantly longer overall survival than patients (n=24) with only DNAH3 mutations.
Conclusions
Our study constitutes the largest neoantigen dataset from integrated genome and transcriptome of CRC to date and illustrates the heterogeneity of the neoantigen landscape among CRC subtypes. The identified neoantigens may contribute to future individualized CRC immunotherapies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Uppsala University; Umeå University; BGI-Shenzhen.
Funding
The Swedish Cancer Society; the Uppsala Cancer Foundation; the Guangdong Provincial Key Laboratory of Human Disease Genomics; the Swedish Government (CancerUU); the Erling-Persson Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
570P - Subclasses of microsatellite-instability colorectal cancer with unique molecular features and immune cell infiltration patterns
Presenter: Kui Wu
Session: Poster session 10
571P - Artificial intelligence-powered analysis of tumor lymphocytes infiltration: A translational analysis of AtezoTRIBE trial
Presenter: Martina Carullo
Session: Poster session 10
574P - Comparative analysis of the tumor immune microenvironment (TIME) in primary and metastatic sites of microsatellite stable (MSS) and microsatellite instability-high (MSI) colorectal cancer
Presenter: Marwan Fakih
Session: Poster session 10
575P - Impact of immunological alterations and post-operative biomarkers on long-term outcomes in patients with locally advanced rectal cancer: Results from the STAR-01 study cohort
Presenter: Francesca Negri
Session: Poster session 10
576P - Prognostic values of a modified diagnostic biopsy-adapted immunoscore based on double immunohistochemical staining in patients with locally advanced rectal cancer
Presenter: Qiang Zeng
Session: Poster session 10
577P - Systematically assessing the intratissue microbiota in 937 patients with colorectal cancer
Presenter: Huanzi Zhong
Session: Poster session 10
578P - Tissue-resident microbiota characterization in colorectal cancer metastases
Presenter: Philippe Stevens
Session: Poster session 10
579P - A clinico-imaging predictive artificial intelligence model of relapse in colon cancer using baseline CT scans
Presenter: América Bueno Gómez
Session: Poster session 10
580P - Prognosis in stage II colorectal cancer: The effect of the primary tumor location and biomarkers
Presenter: Vincent Liégeois
Session: Poster session 10